29 Jul 2022 16:30
29 July 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Result of AGM
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were passed. The results of the proxy voting for the AGM are set out below:
Resolution | Total votes For1 | % of votes cast2 | Total Votes Against | % of votes cast2 | Votes Withheld3 |
1. To receive the audited financial statements and the Auditor's and Directors reports for the year ended 31 December 2021 | 186,380,372 | 88.84 | 23,401,405 | 11.16 | 8,237 |
2. To re-appoint Michael Bradfield as a Director of the Company | 209,005,437 | 99.63 | 777,004 | 0.37 | 7,573 |
3. To re-appoint Hans von Celsing as a Director of the Company | 186,340,437 | 88.84 | 23,402,004 | 11.16 | 7,573 |
4. To re-appoint Lori Cross as a Director of the Company | 208,965,437 | 99.63 | 777,004 | 0.37 | 7,573 |
5. To re-appoint Prof. Steve Myers as a Director of the Company | 209,005,437 | 99.63 | 777,004 | 0.37 | 7,573 |
6. To re-appoint Dr Nick Plowman as a Director of the Company | 208,965,437 | 99.63 | 777,004 | 0.37 | 7,573 |
7. To re-appoint Nicolas Serandour as a Director of the Company | 208,965,437 | 99.63 | 777,004 | 0.37 | 7,573 |
8. To re-appoint Dr Michael Sinclair as a Director of the Company | 209,005,437 | 99.63 | 777,170 | 0.37 | 7,407 |
9. To re-appoint Dr Enrico Vanni as a Director of the Company | 186,340,437 | 88.84 | 23,402,004 | 11.16 | 7,573 |
10. To re-appoint Renhua Zhang as a Director of the Company | 208,965,437 | 99.63 | 777,004 | 0.37 | 7,573 |
11. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company | 178,595,773 | 85.13 | 31,186,834 | 14.87 | 7,407 |
12. To authorise the Directors to determine the remuneration of the Auditors | 208,998,603 | 99.63 | 781,504 | 0.37 | 9,907 |
13. That the Directors be authorised to allot shares and/or to grant rights to subscribe for, or to convert any securities into shares in the Company | 208,778,437 | 99.52 | 1,001,670 | 0.48 | 9,907 |
14. That, subject to Resolution 13, the Directors be empowered to allot equity securities as if section 561 of the Act did not apply | 186,025,264 | 88.68 | 23,754,677 | 11.32 | 9,907 |
Notes
1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution
- ENDS -
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO |
|
| |
Allenby Capital Limited (Nomad and Joint Broker) | |
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) | Tel: +44 (0) 20 3328 5656 |
SI Capital Ltd (Joint Broker) |
|
Nick Emerson | Tel: +44 (0) 1483 413 500 |
Jon Levinson | Tel: +44 (0) 20 3871 4066 |
| |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.